A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT04988308
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Forcare Clinical Research, Inc., Tampa, Florida, United States
🇺🇸Allcutis Research, Beverly, Massachusetts, United States
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 776
- Registration Number
- NCT04988295
- Locations
- 🇮🇹
Istituto Nazionale Tumori Regina Elena, Roma, Italy
🇮🇹Policlinico G.B.Rossi, Verona, Italy
🇯🇵National Hospital Organization Shibukawa Medical Center, Gunma, Japan
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04985955
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT04985812
- Locations
- 🇪🇸
Hosp Univ A Coruna, A Coruna, Spain
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸GCSP/CIS Orland Park, Orland Park, Illinois, United States
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT04978337
- Locations
- 🇺🇸
Pines Care Research Center Inc, Pembroke Pines, Florida, United States
🇺🇸Renovatio Clinical, The Woodlands, Texas, United States
🇺🇸Frontier Clinical Research, Morgantown, West Virginia, United States
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04973566
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
- Conditions
- Sjogren's Syndrome
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04968912
- Locations
- 🇫🇷
CHU de Grenoble Hopital Albert Michallon, La Tronche, France
🇮🇹IRCCS Ospedale San Raffaele, Milano, Italy
🇨🇳Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT04963738
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04960124
- Locations
- 🇩🇪
APEX GmbH, Munchen, Germany
🇩🇪CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT04951622
- Locations
- 🇮🇹
Istituto Neurologico Carlo Besta, Milano, Italy
🇪🇸Hosp. Univ. I Politecni La Fe, Valencia, Spain
🇸🇪Karlstad Central Hospital, Karlstad, Sweden